Multicenter Study Comparing AI-Based Navicam vs. Conventional Pillcam in Small Bowel Pathology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

147 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-27

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since its introduction in 2001, small bowel capsule endoscopy has been pivotal in diagnosing small bowel pathology due to its minimally invasive nature and high diagnostic accuracy. However, the technology has limitations, including prolonged reading times and the need for specialized endoscopists. The Navicam endoscopic capsule, leveraging artificial intelligence (AI) with ProScan™ for automated reading, promises to address these limitations by reducing reading times and enhancing diagnostic efficiency.

This study aims to assess the diagnostic concordance and to compare the efficiency of the AI-based Navicam capsule with the conventional Pillcam SB3 in the exploration of the small bowel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases

NCT05086471

Small Bowel Disease

COMPLETED NA

Role of AI in CE for the Identification of SB Lesions in Patients With Small Intestinal Bleeding.

NCT04821349

Iron Deficiency Anemia Obscure Gastrointestinal Bleeding

COMPLETED NA

Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study)

NCT05450393

Small Intestine Disease Small Intestine Cancer Small Intestinal Ulcer Bleeding +3 more

WITHDRAWN

Evaluation of Neoplasia With Artificial Intelligence in Gastrointestinal Endoscopy

NCT04937647

Gastrointestinal Neoplasms

RECRUITING

Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule

NCT01820182

Anemia Gastrointestinal Bleedings Méléna +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicenter, randomized, observational study involving multiple hospitals across Spain. At each site, patients will ingest both the Pillcam SB3 and Navicam capsules in a randomized order. Reading times, transit times, and diagnostic yield will be compared between the two devices. A central reading committee of experienced gastroenterologists will conduct blinded evaluations of both explorations using predefined criteria.

The primary endpoint is the diagnostic concordance between Navicam's AI-driven ProScan™ system and the conventional reading of Pillcam SB3, measured by Cohen's kappa index.

The secondary endpoints include to assess the correlation in lesion detection, video download times, gastric and small bowel transit times, total reading times, and adverse events.

The sample size is 147 patients, accounting for an expected 10% dropout rate, based on previous studies showing a diagnostic concordance kappa index of 0.6.

This study aims to establish that the AI-based Navicam capsule is at least as effective as the conventional Pillcam SB3 in diagnosing small bowel lesions, with potentially reduced reading times, thus enhancing clinical efficiency in small bowel diagnostics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Intestine Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Navicam endoscopic capsule

Navicam endoscopic capsule device for the study of small bowel pathology.

Group Type EXPERIMENTAL

Navicam SB capsule

Intervention Type DEVICE

Exploration of the small bowel by Navicam SB endoscopic capsule.

Pillcam endoscopic capsule

Pillcam SB3 endoscopic capsule device for the study of small bowel pathology.

Group Type ACTIVE_COMPARATOR

Pillcam SB3

Intervention Type DEVICE

Exploration of the small bowel by Pillcam SB3 endoscopic capsule.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Navicam SB capsule

Exploration of the small bowel by Navicam SB endoscopic capsule.

Intervention Type DEVICE

Pillcam SB3

Exploration of the small bowel by Pillcam SB3 endoscopic capsule.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients over 18 years of age with any clinical indication to undergo a small bowel exploration using capsule endoscopy at the participating hospital.

Exclusion Criteria

* Patients with known small bowel strictures detected by computed tomography (CT) or magnetic resonance imaging (MRI).
* Patients with a history of esophagogastric and small bowel surgery (excluding ileocecal resection).
* Patients with a clinical contraindication for small bowel capsule endoscopy.
* Hospitalized patients.
* Patients with pacemaker or Implantable Cardioverter Defibrillator (ICD).
* Patients scheduled for a MRI within 15 days after capsule endoscopy ingestion.
* Pregnant or actively breastfeeding patients.
* Patients with swallowing disorders requiring endoscopic placement of the capsule.
* Simultaneous participation in another clinical trial using any investigational drug or device.
* Concurrent life-threatening pathology or condition.
* Inability to sign the informed consent form.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Begoña González Suárez, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Clinic of Barcelona

Locations

Explore where the study is taking place and check the recruitment status at each participating site.